Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis-Reference-Cited by-同舟云学术

Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis

Published:2023-10-06 Issue:11 Volume:13 Page:2839-2857
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Armstrong April W.^ORCID,Warren Richard B.^ORCID,Zhong Yichen,Zhuo Joe,Cichewicz Allie^ORCID,Kadambi Ananth^ORCID,Junqueira Daniela^ORCID,Westley Tracy,Kisa Renata,Daamen Carolin,Augustin Matthias^ORCID

Funder

Bristol-Myers Squibb

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

https://link.springer.com/content/pdf/10.1007/s13555-023-01034-7.pdf

Reference120 articles.

1. Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29–39.

2. Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, Program fOr Evaluation of TYK2 inhibitor psoriasis second phase 3 trial. J Am Acad Dermatol. 2023;88(1):40–51.

3. Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–61.

4. Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385(2):142–52.

5. Reich K, Gooderham M, Thaci D, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576–86.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Baseline Characteristics and Maintenance Therapy Choice on Symptom Control, Reliever Use, Exacerbation Risk in Moderate–Severe Asthma: A Clinical Modelling and Simulation Study;Advances in Therapy;2024-09-06

2. New and emerging oral therapies for psoriasis;Drugs in Context;2024-08-01

3. Comments on ‘Evaluating the safety and efficacy of biologics in psoriatic patients with malignancies: Insights and future directions’;Journal of the European Academy of Dermatology and Venereology;2024-07-14

4. Cost per response analysis of deucravacitinib versus apremilast and first-line biologics among patients with moderate to severe plaque psoriasis in the United States;Journal of Dermatological Treatment;2024-06-24

5. Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation;Expert Opinion on Drug Safety;2024-05-06